EoE Uniquity One – (NSI-8226-201)

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study.

Study Title

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Open-Label Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis (ALAMERE).

Purpose of Study

A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis.

Eligibility

You may be eligible for the study if you meet the following criteria.

How long will this study take?

If enrolled, your participation is expected to last approximately 72 weeks (20 Visits) including the Run-In, Treatment, Open-Label.


Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?

Facebook
Twitter
LinkedIn
Pinterest
Email